FDA declines to approve Bristol-Myers hepatitis drug
November 26, 2014 at 11:56 AM EST
Nov 26 (Reuters) - Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve use of its experimental daclatasvir drug for hepatitis C, in combination with other antiviral drugs.